December 2007 Issue of MMM
So how was it for you? 2007, that is.
Last month, 800 execs flocked to Central Park to see 750-plus entries whittled down to just 24. And it certainly proved to be a night ...
It's election season once again, and everybody's running against Big Pharma. But the industry has bigger problems.
Few analysts have proved as prescient over the years as Morgan Stanley's Jami Rubin, recently ranked third among industry analysts by Institutional Investor.
MM&M takes a detailed look at 258 products in the pipeline, highlighting 17 of them with insights and ratings from top analysts, to provide an ...
Jim Davidson might be the man who saved drug advertising.
For pharmaceutical marketing research, I believe that 2007 constituted a tipping point.
We all like a good mystery, so we tend to overreact and over-personalize infectious threats that are truly remote.
Bruce Bellande, PhD, was pleased to learn that regulators accepted the materials he sent them as adequate proof of corporate separation.
Med Ed Report
New hires in Pfizer's medical education grants (MEG) department signal the firm is moving in a new direction while raising competencies.
Non-accredited providers must comply with the same firewall rules as their accredited counterparts to continue working with them as joint sponsors, according to new guidance.
The nonprofit group working on a credentialing program for people in CME has engaged a national test developer to pilot an exam by May.
PhRMA is working on guidance around transparency of funding for CME, including possibly revising its code on gifts to physicians, sources said. PhRMA did not ...
Ninety-one percent of audience members polled at the National Task Force on CME Provider-Industry Collaboration meeting said they would not support a pooled fund for ...
Sixty percent of medical school department chairs have some form of personal relationship with industry, including serving as a consultant (27%), scientific advisory board member ...
Ray Wolf, PharmD, has joined Sepracor as director, medical education.
Thanks to a partnership, CME LLC is the exclusive provider of psychiatric CME content for ReachMD, XM Radio Channel 157.
Advanstar has named Formulary publisher Trevor Deal to lead Medical Economics.
Elsevier launched a Clinical Solutions Group within its health sciences division to house journals, books and clinical decision support tools aimed at medical researchers, practitioners, ...
Thomson Scientific named Novartis the number one company of 2007 for quality and quantity of scientific literature in its quarterly review, "Who is making the ...
HMP Communications named Bill Norton VP, meetings and trade shows.
Public Library of Science launched an online medical journal devoted to neglected tropical diseases like elephantitis and leptospirosis.
Merion Publications is rebranding Advance for Imaging and Oncology Administrators.
Measuring traffic online can be tough for advertisers, as no two tracking firms ever seem to agree. But, is the lack of standardization in media ...
The Internet has become a primary source of information for people living with disabilities and chronic diseases.
Google is expected to launch its eagerly awaited health initiative sometime in early 2008, according to the company's head of search, Marissa Mayer.
Online juggernauts in the consumer space, Yahoo! and WebMD announced they have inked an exclusive multi-year search and advertising distribution agreement. Financial terms of the ...
The FDA's Division of Drug Marketing, Advertising and Communications (DDMAC) has told Johnson & Johnson's Scios unit to stop distributing promotional computer mousepads and pens ...
Sales, marketing and compliance solutions consulting firm Cegedim Dendrite has hired one of the nation's foremost FDA regulations experts.
Small pharma is taking a cue from its Big Pharma brethren as it trims its sales force size to improve market position.
Informed Medical Communications (IMC), an interactive medical information service company, has named PDI's former president Steven Budd its new CEO.
Lois Smith has joined MediZine as VP of sales and marketing.
RTC Relationship Marketing (RTCRM), a direct marketing agency, has hired Brad Blackmon as VP/account director.
inVentiv Commercial announced a realignment of its business into two divisions.
With Abbott and Medtronic crowding into a market it has long split with Boston Scientific, Johnson & Johnson's Cordis is looking to raise the profile ...
Democratic candidate John Edwards called for a two-year moratorium on TV ads for new drugs.
Bristol-Myers Squibb said its advertising and promotional spend increased by 23% in the third quarter, in part due to increased DTC advertising of Plavix and ...
The Lunesta moth continues to dominate IAG Research's most-recalled drug ads survey.
DDMAC asked companies to notify FDA within 30 days if they intend to participate in the DTC user fee program in 2008 and to identify ...
Treating rare disorders was once considered a "good-will science endeavor," but market forces have encouraged companies to revisit how these small molecules can be big ...
Pfizer and Nektar have buried the hatchet after the former paid the latter $135 million following its abrupt decision to discontinue marketing of Exubera, on ...
Novartis is experimenting with blogging for physicians with melanomaperspectives.com.
How does an oncoming migraine feel? Like an approaching storm. A full-blown attack? Think thunder and lightning.
Reports linking GlaxoSmithKline's Avandia to increased cardiovascular risk, and the drug's subsequent swoon, may prove just the tip of the iceberg for the diabetes field.
As the Bush administration winds down, its agenda has brought some not-so-conservative results for drug marketers.
Enforcement trends in recent years between the FDA's Center for Drugs and its Center for Biologics, as measured by numbers of citations for violating advertising/promotion ...
Independent Vermont senator Bernie Sanders has introduced federal legislation (S. 2210) to replace the current patent and non-patent market exclusivity system for drugs in place ...
Federal preemption arguments failed in October to prevent a Nevada jury from awarding three women $134.5 million in their suit against Wyeth over its hormone ...
FDA commissioner Andrew von Eschenbach has approved creation of an agency Pediatric Review Committee (PeRC) to provide consultation on and general review of pediatric information ...
A CSL Behring LLC direct-to-consumer promotional brochure and site (www.HemophiliaB.com) for Mononine (coagulation Factor IX) has been cited by the FDA's biologics Center for making ...
The FDA has approved some labeling changes to erectile dysfunction drugs— including Viagra, Cialis, and Levitra—to display more prominently an existing risk on the potential ...
Eli Lilly & Co. says updated labeling for its atypical antipsychotics Zyprexa (olanzapine) and Symbyax (olanzapine and fluoxetine HCl) reflects recently completed pooled analyses of ...
Former FDA deputy chief counsel Gerald F. Masoudi has rejoined the agency as its new chief counsel, replacing Sheldon Bradshaw who left the agency in ...
Pardon my French, but there's no better cliché to describe a special issue of Harper's magazine dated October 1960, starting with the cover headline: "The ...
- McCann Health forms new global consultancy
- Alexion uses superheroes, social media to raise rare-disease awareness
- Five things for pharma marketers to know: Tuesday, September 20, 2016
- Five things for pharma marketers to know: Monday, September 26, 2016
- Five things for pharma marketers to know: Wednesday, September 21, 2016
- Merck educates doctors about biosimilars, long before it will sell one in the U.S.
- 4 trends with the potential to change behavior in the patient journey
- When it comes to professional ads, print makes its comeback
- 2016 Pharma Report: All the data in one place
- What do physicians think about biosimilars?
- Five things for pharma marketers to know: Tuesday, September 27, 2016
- The EpiPen Debate Reveals Gap in Industry's Pricing Defense
- Uber partners with startup to take patients to the doctor
- The FDA denies approval of abuse-deterrent opioid after promotional warning
- Five things for pharma marketers to know: Monday, September 26, 2016